Advertisement

Hypoglycemia in Diabetes Mellitus

  • Mazen Alsahli
  • John E. GerichEmail author
Reference work entry

Abstract

Hypoglycemia is a frequent occurrence for many patients with diabetes treated with insulin or insulin secretagogues. Episodes of hypoglycemia have significant morbidity and mortality and are the main limiting factor for achieving near optimal glycemic control. Risk factors including impaired glucose counterregulation and hypoglycemia unawareness are largely preventable and/or reversible. This chapter summarizes our current knowledge of the epidemiology, pathogenesis, risk factors, and complications of hypoglycemia in patients with diabetes and discusses prevention and treatment strategies.

Keywords

Type 1 diabetes Type 2 diabetes Hypoglycemia Hypoglycemia counterregulation 

Abbreviations

CKD

Chronic kidney disease

T1DM

Type 1 diabetes mellitus

T2DM

Type 2 diabetes mellitus

References

  1. 1.
    Owen O, Morgan A, Kemp H, Sullivan J, Herrera M, Cahill G. Brain metabolism during fasting. J Clin Invest. 1967;46:1589–95.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Cryer P. Banting Lecture: hypoglycemia, the limiting factor in the management of IDDM. Diabetes. 1994;43:1378–89.PubMedCrossRefGoogle Scholar
  3. 3.
    Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384–95.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Gerich J. Hypoglycemia and counterregulation in type 2 diabetes. Lancet. 2000;356(9246):19467.CrossRefGoogle Scholar
  5. 5.
    Mokan M, Mitrakou M, Veneman T, Ryan C, Korytkowski M, Cryer P, Gerich J. Hypoglycemia unawareness in IDDM. Diabetes Care. 1994;17:1397–403.PubMedCrossRefGoogle Scholar
  6. 6.
    Guillod L, Comte-Perret S, Monbaron D, Gaillard RC, Ruiz J. Nocturnal hypoglycaemias in type 1 diabetic patients: what can we learn with continuous glucose monitoring? Diabetes Metab. 2007;33:360–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Wentholt IM, Maran A, Masurel N, Heine RJ, Hoekstra JB, DeVries JH. Nocturnal hypoglycaemia in type 1 diabetic patients, assessed with continuous glucose monitoring: frequency, duration and associations. Diabet Med. 2007;24:527–32.PubMedCrossRefGoogle Scholar
  8. 8.
    Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, Frier BM, Morris AD. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26:1176–80.PubMedCrossRefGoogle Scholar
  9. 9.
    Hypoglycemia Study Group UK. Risk of hypoglycemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–7.CrossRefGoogle Scholar
  10. 10.
    Akram K, Pedersen-Bjergaael U, Borch-Johnson K, Thorsteinsson B. Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: a literature survey. J Diabetes Complications. 2006;20:402–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycemia in type 2 diabetes. Diabet Med. 2008;25:245–54.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRefGoogle Scholar
  13. 13.
    van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol. 1997;50:735–41.PubMedCrossRefGoogle Scholar
  14. 14.
    Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30:389–94.PubMedCrossRefGoogle Scholar
  15. 15.
    Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK, 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–47.PubMedCrossRefGoogle Scholar
  16. 16.
    Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes. Diabetes Care. 2005;28:2948–61.PubMedCrossRefGoogle Scholar
  17. 17.
    Cersosimo E, Garlick P, Ferretti J. Renal glucose production during insulin-induced hypoglycemia in humans. Diabetes. 1999;48:261–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Meyer C, Dostou J, Gerich J. Role of the human kidney in glucose counterregulation. Diabetes. 1999;48:943–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Schwartz N, Clutter W, Shah S, Cryer P. The glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest. 1987;79:777–81.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Meyer C, Grosmann R, Mitrakou A, Mahler R, Veneman T, Gerich J, Bretzel R. Effects of autonomic neuropathy on counterregulation and awareness of hypoglycemia in type 1 diabetic patients. Diabetes Care. 1998;21:1960–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I, Durrant J, Cryer P, Gerich J. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol. 1991;260:E67–74.PubMedGoogle Scholar
  22. 22.
    Fanelli C, Pampanelli S, Epifano L, Rambotti A, Ciofetta M, Modarelli F, DiVincenzo A, Annibale B, Lepore M, Lalli C, DelSindaco P, Brunetti P, Bolli G. Relative roles of insulin and hypoglycemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycemia in male and female humans. Diabetologia. 1994;37:797–807.PubMedCrossRefGoogle Scholar
  23. 23.
    DeFeo P, Perriello G, Torlone E, Ventura M, Santeusanio F, Brunetti P, Gerich J, Bolli G. Demonstration of a role of growth hormone in glucose counterregulation. Am J Physiol. 1989;256:E835–43.Google Scholar
  24. 24.
    DeFeo P, Perriello G, Torlone E, Ventura M, Fanelli C, Santeusanio F, Brunetti P, Gerich J, Bolli G. Contribution of cortisol to glucose counterregulation in humans. Am J Physiol. 1989;257:E35–42.Google Scholar
  25. 25.
    Hepburn D, Deary I, Frier B, Patrick A, Quinn J, Fisher B. Symptoms of acute insulin-induced hypoglycemia in humans with and without IDDM. Factor-analysis approach. Diabetes Care. 1991;14:949–57.PubMedCrossRefGoogle Scholar
  26. 26.
    Towler D, Havlin C, Craft S, Cryer P. Mechanism of awareness of hypoglycemia: perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes. 1993;42:1791–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Cox D, Gonder-Frederick L, Antoun B, Cryer P, Clarke W. Perceived symptoms in the recognition of hypoglycemia. Diabetes Care. 1993;16:519–27.PubMedCrossRefGoogle Scholar
  28. 28.
    Bolli G, DeFeo P, Perriello G, DeCosmo S, Ventura M, Campbell P, Brunetti P, Gerich J. Role of hepatic autoregulation in defense against hypoglycemia in humans. J Clin Invest. 1985;75:1623–31.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Mitrakou A, Fanelli C, Veneman T, Perriello G, Calderone S, Plantanisiotis D, Rambotti A, Raptis S, Brunetti P, Cryer P, Gerich J, Bolli G. Reversibility of unawareness of hypoglycemia in patients with insulinomas. N Engl J Med. 1993;329:834–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Bolli G, DeFeo P, Compagnucci P, Cartechini M, Angeletti G, Santeusanio F, Brunetti P, Gerich J. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus: interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes. 1983;32:134–41.PubMedCrossRefGoogle Scholar
  31. 31.
    Gerich J, Langlois M, Noacco C, Karam J, Forsham P. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha-cell defect. Science. 1973;182:171–3.PubMedCrossRefGoogle Scholar
  32. 32.
    Fukuda M, Tanaka A, Tahara Y, Ikegami H, Yamamoto Y, Kumahara Y, Shima K. Correlation between minimal secretory capacity of pancreatic ß-cells and stability of diabetic control. Diabetes. 1988;37:81–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Rizza R, Cryer P, Gerich J. Role of glucagon, epinephrine and growth hormone in glucose counterregulation. J Clin Invest. 1979;64:62–71.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Hirsch B, Shamoon H. Defective epinephrine and growth hormone responses in type I diabetes are stimulus specific. Diabetes. 1987;36:20–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Dagogo-Jack S, Craft S, Cryer P. Hypoglycemia-associated autonomic failure in insulin dependent diabetes mellitus. J Clin Invest. 1993;91:819–28.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    White N, Skor D, Cryer P, Bier D, Levandoski L, Santiago J. Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med. 1983;308:485–91.PubMedCrossRefGoogle Scholar
  37. 37.
    Bolli G, DeFeo P, DeCosmo S, Perriello G, Ventura M, Benedetti M, Santeusanio F, Gerich J, Brunetti P. A reliable and reproducible test for adequate glucose counterregulation in type I diabetes mellitus. Diabetes. 1984;33:732–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Cersosimo E, Ferretti J, Sasvary D, Garlick P. Adrenergic stimulation of renal glucose release is impaired in type 1 diabetes. Diabetes. 2001;50 Suppl 2:A54.Google Scholar
  39. 39.
    Amiel S. R.D. Lawrence Lecture 1994. Limits of normality: the mechanisms of hypoglycemia unawareness. Diabet Med. 1994;11:918–24.PubMedCrossRefGoogle Scholar
  40. 40.
    Gold A, MacLeod K, Frier B. Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia. Diabetes Care. 1994;17:697–703.PubMedCrossRefGoogle Scholar
  41. 41.
    Pramming S, Thorsteinsson B, Bendtson I, Binder C. Symptomatic hypoglycemia in 411 type I diabetic patients. Diabet Med. 1991;8:217–22.PubMedCrossRefGoogle Scholar
  42. 42.
    Hepburn D, Patrick A, Eadington D, Ewing D, Frier B. Unawareness of hypoglycemia in insulin-treated diabetic patients: prevalence and relationship to autonomic neuropathy. Diabet Med. 1990;7:711–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Macdonald PE, Marinis YZ, Ramracheya R, et al. A KATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans. PLoS Biol. 2007;5, e143.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Munoz A, Hu M, Hussain K, Bryan J, Aguilar-Bryan L, Rajan AS. Regulation of glucagon secretion at low glucose concentrations: evidence for adenosine triphosphate-sensitive potassium channel involvement. Endocrinology. 2005;146:5514–21.PubMedCrossRefGoogle Scholar
  45. 45.
    Rorsman P, Ramracheya R, Rorsman NJ, Zhang Q. ATP-regulated potassium channels and voltage-gated calcium channels in pancreatic alpha and beta cells: similar functions but reciprocal effects on secretion. Diabetologia. 2014;57(9):1749–61.PubMedCrossRefGoogle Scholar
  46. 46.
    Reno CM, Litvin M, Clark AL, Fisher SJ. Defective counterregulation and hypoglycemia unawareness in diabetes: mechanisms and emerging treatments. Endocrinol Metab Clin North Am. 2013;42(1):15–38.PubMedCrossRefGoogle Scholar
  47. 47.
    Korytkowski MT, Mokan M, Veneman TF, Mitrakou A, Cryer P, Gerich JE. Reduced beta-adrenergic sensitivity in patients with type 1 diabetes and hypoglycemia unawareness. Diabetes Care. 1998;21(11):1939–43.PubMedCrossRefGoogle Scholar
  48. 48.
    Fritsche A, Stumvoll M, Grüb M, Sieslack S, Renn W, Schmülling RM, Häring HU, Gerich JE. Effect of hypoglycemia on beta-adrenergic sensitivity in normal and type 1 diabetic subjects. Diabetes Care. 1998;21(9):1505–10.PubMedCrossRefGoogle Scholar
  49. 49.
    Trovik TS, Jaeger R, Jorde R, Sager G. Reduced beta-adrenergic sensitivity in healthy volunteers induced by hypoglycemia. Fundam Clin Pharmacol. 1995;9(2):181–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Heller S, MacDonald I, Tattersall R. Counterregulation in type 2 (noninsulin-dependent) diabetes mellitus: normal endocrine and glycemic responses, up to 10 years after diagnosis. Diabetologia. 1987;30:924–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Levy C, Kinsley B, Bajaj M, Simonson D. Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM. Diabetes Care. 1998;21:1330–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Shamoon H, Friedman S, Canton C, Zacharowicz L, Hu M, Rossetti L. Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus. J Clin Invest. 1994;93:2562–71.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Segel S, Paramore D, Cryer P. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002;51:724–33.PubMedCrossRefGoogle Scholar
  54. 54.
    Bolli G, Tsalikian E, Haymond M, Cryer P, Gerich J. Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. J Clin Invest. 1984;73:1532–41.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Alsahli M, Gerich JE. Hypoglycemia in patients with renal disease. J Clin Med. 2015;4(5):948–64.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Alsahli M, Gerich JE. Hypoglycemia. Endocrinol Metab Clin North Am. 2013;42(4):657–76.PubMedCrossRefGoogle Scholar
  57. 57.
    Murad MH, Coto-Yglesias F, Wang AT, Sheidaee N, Mullan RJ, Elamin MB, Erwin PJ, Montori VM. Drug-induced hypoglycmia: a systemic review. J Clin Endocrinol Metab. 2009;94:741–5.PubMedCrossRefGoogle Scholar
  58. 58.
    Miholic J, Orskov C, Holst J, Kotzerke J, Meyer H. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci. 1991;36:1361–70.PubMedCrossRefGoogle Scholar
  59. 59.
    Wapnick S, Jones JJ. Changes in glucose tolerance and serum insulin following partial gastrectomy and intestinal resection. Gut. 1972;13:871–3.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Leichter S, Permutt M. Effect of adrenergic agents on postgastrectomy hypoglycemia. Diabetes. 1975;24:1005–10.PubMedCrossRefGoogle Scholar
  61. 61.
    Shultz KT, Neelon FA, Nilsen LB, Lebovitz HE. Mechanism of postgastrectomy hypoglycemia. Arch Intern Med. 1971;128:240–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gniuli D, Mari A, Nanni G, Castagneto M, Calvani M, Mingrone G. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006;55:2025–31.PubMedCrossRefGoogle Scholar
  63. 63.
    Gumbs AA, Modlin IM, Ballantyne GH. Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obes Surg. 2005;15:462–73.PubMedCrossRefGoogle Scholar
  64. 64.
    Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Livingston EH, Nguyen NT, Li Z, Mojica WA, Hilton L, Rhodes S, Morton SC, Shekelle PG. Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005;142:547–59.PubMedCrossRefGoogle Scholar
  65. 65.
    Gebhard B, Holst JJ, Biegelmayer C, Miholic J. Postprandial GLP-1, norepinephrine, and reactive hypoglycemia in dumping syndrome. Dig Dis Sci. 2001;46:1915–23.PubMedCrossRefGoogle Scholar
  66. 66.
    Lawaetz O, Blackburn AM, Bloom SR, Aritas Y, Ralphs DN. Gut hormone profile and gastric emptying in the dumping syndrome. A hypothesis concerning the pathogenesis. Scand J Gastroenterol. 1983;18:73–80.PubMedCrossRefGoogle Scholar
  67. 67.
    Dube PE, Brubaker PL. Nutrient, neural and endocrine control of glucagon-like peptide secretion. Horm Metab Res. 2004;36:755–60.PubMedCrossRefGoogle Scholar
  68. 68.
    Kellum JM, Kuemmerle JF, O’Dorisio TM, Rayford P, Martin D, Engle K, Wolf L, Sugerman HJ. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg. 1990;211:763–70.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623–30.PubMedCrossRefGoogle Scholar
  70. 70.
    Patti ME, McMahon G, Mun EC, Bitton A, Holst JJ, Goldsmith J, Hanto DW, Callery M, Arky R, Nose V, Bonner-Weir S, Goldfine AB. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia. 2005;48:2236–40.PubMedCrossRefGoogle Scholar
  71. 71.
    Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med. 2005;353:249–54.PubMedCrossRefGoogle Scholar
  72. 72.
    Won JG, Tseng HS, Yang AH, Tang KT, Jap TS, Lee CH, Lin HD, Burcus N, Pittenger G, Vinik A. Clinical features and morphological characterization of 10 patients with noninsulinoma pancreatogenous hypoglycaemia syndrome (NIPHS). Clin Endocrinol (Oxf). 2006;65:566–78.CrossRefGoogle Scholar
  73. 73.
    Meier JJ, Butler AE, Galasso R, Butler PC. Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. Diabetes Care. 2006;29:1554–9.PubMedCrossRefGoogle Scholar
  74. 74.
    McLaughlin T, Peck M, Holst J, Deacon C. Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery. J Clin Endocrinol Metab. 2010;95(4):1851–5.PubMedCrossRefGoogle Scholar
  75. 75.
    Campos GM, Ziemelis M, Paparodis R, Ahmed M, Davis DB. Laparoscopic reversal of Roux-en-Y gastric bypass: technique and utility for treatment of endocrine complications. Surg Obes Relat Dis. 2014;10(1):36.PubMedCrossRefGoogle Scholar
  76. 76.
    Lee CJ, Brown T, Magnuson TH, Egan JM, Carlson O, Elahi D. Hormonal response to a mixed-meal challenge after reversal of gastric bypass for hypoglycemia. J Clin Endocrinol Metab. 2013;98(7):E1208–12.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Salehi M, Gatadelli A, D’Alessio DA. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. Gastroenterology. 2014;146(3):669–80.PubMedCrossRefGoogle Scholar
  78. 78.
    Wredling R, Levander S, Adamson U, Lins P. Permanent neuropsychological impairment after recurrent episodes of severe hypoglycaemia in man. Diabetologia. 1990;33:152–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Patrick A, Campbell I. Fatal hypoglycaemia in insulin-treated diabetes mellitus: clinical features and neuropathological changes. Diabet Med. 1990;7:349–54.PubMedCrossRefGoogle Scholar
  80. 80.
    Perros P, Frier B. The long-term sequelae of severe hypoglycemia on the brain in insulin-dependent diabetes mellitus. Horm Metab Res. 1997;29:197–202.PubMedCrossRefGoogle Scholar
  81. 81.
    Deary I, Crawford J, Hepburn D, Langan S, Blackmore L, Frier B. Severe hypoglycemia and intelligence in adult patients with insulin-treated diabetes. Diabetes. 1993;42:341–4.PubMedCrossRefGoogle Scholar
  82. 82.
    Reno CM, Daphna-Iken D, Chen YS, VanderWeele J, Jethi K, Fisher SJ. Severe hypoglycemia–induced lethal cardiac arrhythmias are mediated by sympathoadrenal activation. Diabetes. 2013;62(10):3570–81.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol. 2014;10:711–22.PubMedCrossRefGoogle Scholar
  84. 84.
    Fisher B, Quin J, Rumley A, Lennie S, Small M, MacCuish A, Lowe G. Effects of acute insulin-induced hypoglycaemia on haemostasis, fibrinolysis and haemorheology in insulin-dependent diabetic patients and control subjects. Clin Sci. 1991;80:525–31.PubMedCrossRefGoogle Scholar
  85. 85.
    Joy NG, Tate DB, Younk LM, Davis SN. Effects of acute and antecedent hypoglycemia on endothelial function and markers of atherothrombotic balance in healthy humans. Diabetes. 2015;64:2571–80.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Duh E, Feinglos M. Hypoglycemia-induced angina pectoris in a patient with diabetes mellitus. Ann Intern Med. 1994;121:945–6.PubMedCrossRefGoogle Scholar
  87. 87.
    Cryer PE. Hypoglycemia-Associated Autonomic Failure in diabetes: maladaptive, adaptive, or both? Diabetes. 2015;64(7):2322–3.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    VanderWeele JJ, Daphna-Iken D, Chen YS, Hoffman RS, Clark AL, Fisher SJ. Antecedent recurrent hypoglycemia reduces lethal cardiac arrhythmias induced by severe hypoglycemia in diabetic rats. Diabetes. 2014;53 Suppl 1:A39.Google Scholar
  89. 89.
    Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm Jr RH, Probstfield JL, Simons-Morton DG, Friedewald WT, Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.PubMedCrossRefGoogle Scholar
  90. 90.
    Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F, ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.PubMedCrossRefGoogle Scholar
  91. 91.
    Kohner E, McLeod D, Marshall J. Complications of diabetes. London: Edward Arnold; 1982.Google Scholar
  92. 92.
    Rhoads GG, Orsini LS, Crown W, Wang S, Getahun D, Zhang Q. Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes. J Occup Environ Med. 2005;47:447–52.PubMedCrossRefGoogle Scholar
  93. 93.
    Curkendall SM, Natoli JL, Alexander CM, Nathanson BH, Haidar T, Dubois RW. Economic and clinical impact of inpatient diabetic hypoglycemia. Endocr Pract. 2009;15:302–12.PubMedCrossRefGoogle Scholar
  94. 94.
    Paz-Guevara A, Hsu T-H, White P. Juvenile diabetes mellitus after forty years. Diabetes. 1975;24:559–65.PubMedCrossRefGoogle Scholar
  95. 95.
    Nabarro J, Mustaffa B, Morris D, Walport M, Kurtz A. Insulin deficient diabetes. Contrasts with other endocrine deficiencies. Diabetologia. 1979;16:5–12.PubMedCrossRefGoogle Scholar
  96. 96.
    Seltzer H. Severe drug-induced hypoglycemia: a review. Compr Ther. 1979;5:21–9.PubMedGoogle Scholar
  97. 97.
    Berger W, Caduff F, Pasquel M, Rump A. Die relative haufigkeit der schweren Sulfonylharnstoff- hypoglykamie in den letzten 25 Jahren in der Schweiz. Schwerz Med Wschr. 1986;116:145–51.Google Scholar
  98. 98.
    Gaston S. Outcomes of hypoglycemia treated by standardized protocol in a community hospital. Diabetes Educ. 1992;18:491–4.PubMedCrossRefGoogle Scholar
  99. 99.
    Slama G, Traynard P, Desplanque N, Pudar H, Dhunputh I, Letanoux M, Bornet F, Tchobroutsky G. The search for an optimized treatment of hypoglycemia. Carbohydrates in tablets, solution, or gel for the correction of insulin reactions. Arch Intern Med. 1990;150:589–93.PubMedCrossRefGoogle Scholar
  100. 100.
    Palatnick W, Meatherall R, Tenenbein M. Clinical spectrum of sulfonylurea overdose and experience with diazoxide therapy. Arch Intern Med. 1991;151:1859–62.PubMedCrossRefGoogle Scholar
  101. 101.
    Cryer P, Gerich J. Glucose counterregulation, hypoglycemia, and intensive insulin therapy in diabetes mellitus. N Engl J Med. 1985;313:232–41.PubMedCrossRefGoogle Scholar
  102. 102.
    Bolli G. How to ameliorate the problem of hypoglycemia in intensive as well as nonintensive treatment of type 1 diabetes. Diabetes Care. 1999;22 Suppl 2:B43–52.PubMedGoogle Scholar
  103. 103.
    American Diabetes Association. Standards of medical care in diabetes 2015. Diabetes Care. 2015;38 Suppl 1:S58–66.CrossRefGoogle Scholar
  104. 104.
    Cox D, Ritterband L, Magee J, Clarke W, Gonder-Frederick L. Blood glucose awareness training delivered over the internet. Diabetes Care. 2008;31(8):1527–8.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Samann A, Muhlhauser I, Bender R, Kloos C, Muller UA. Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study. Diabetologia. 2005;48:1965–70.PubMedCrossRefGoogle Scholar
  106. 106.
    The DAFNE Study Group. Training in flexible intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomized controlled trial. BMJ. 2002;325:746–52.CrossRefGoogle Scholar
  107. 107.
    Brunelle R, Llewelyn J, Anderson J, Gale E, Koivisto V. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care. 1998;21:1726–31.PubMedCrossRefGoogle Scholar
  108. 108.
    Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care. 2004;27:1081–7.PubMedCrossRefGoogle Scholar
  109. 109.
    Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28:950–5.PubMedCrossRefGoogle Scholar
  110. 110.
    Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269–74.PubMedCrossRefGoogle Scholar
  111. 111.
    Boland E, Grey M, Oesterle A, Fredrickson L, Tamborlane W. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care. 1999;22:1779–84.PubMedCrossRefGoogle Scholar
  112. 112.
    Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25:765–74.PubMedCrossRefGoogle Scholar
  113. 113.
    Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring (JDRF-CGM) trial. N Engl J Med. 2010;363:311–20.CrossRefGoogle Scholar
  114. 114.
    Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA, STAR 3 Study Group. Effectiveness of sensor augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311–20.PubMedCrossRefGoogle Scholar
  115. 115.
    Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011;34(4):795–800.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Dagogo-Jack S, Rattarason C, Cryer P. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation in IDDM. Diabetes. 1994;43:1426–34.PubMedCrossRefGoogle Scholar
  117. 117.
    Fritsche A, Stumvoll M, Haring H, Gerich J. Reversal of hypoglycemia unawareness in a long-term type 1 diabetic patient by improvement of beta-adrenergic sensitivity after prevention of hypoglycemia. J Clin Endocrinol Metab. 2000;85:523–5.PubMedGoogle Scholar
  118. 118.
    Fanelli C, Epifano L, Rambotti A, Pampanelli S, Di Vincenzo A, Modarelli F, Lepore M, Annibale B, Ciofetta M, Bottini P, Porcellati F, Scionti L, Santeusanio F, Brunetti P, Bolli G. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes. 1993;42:1683–9.PubMedCrossRefGoogle Scholar
  119. 119.
    Fanelli C, Pampanelli S, Epifano L, Rambotti A, Vincenzo A, Modarelli F, Ciofetta M, Lepore M, Annibale B, Torlone E, Perriello G, DeFeo P, Santeusano F, Brunetti P, Bolli G. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia. 1994;37:1265–76.PubMedCrossRefGoogle Scholar
  120. 120.
    Cranston I, Lomas J, Maran A, MacDonald I, Amiel S. Restoration of hypoglycemia unawareness in patients with long- duration insulin-dependent diabetes. Lancet. 1994;344:283–7.PubMedCrossRefGoogle Scholar
  121. 121.
    Davis M, Mellman M, Friedman S, Chang C, Shamoon H. Recovery of epinephrire response but not hypoglycemic symptom threshold after intensive therapy in type 1 diabetes. Am J Med. 1994;97:535–42.PubMedCrossRefGoogle Scholar
  122. 122.
    Kendall D, Teuscher A, Robertson R. Defective glucagon secretion during sustained hypoglycemia following successful islet allo- and autotransplantation in humans. Diabetes. 1997;46:23–7.PubMedCrossRefGoogle Scholar
  123. 123.
    Meyer C, Hering B, Grosmann R, Brandhorst H, Brandhorst D, Gerich J, Federlin K, Bretzel R. Improved glucose counterregulation and autonomic symptoms after intraportal islet transplants alone in patients with long-standing type I diabetes mellitus. Transplantation. 1998;66:233–40.PubMedCrossRefGoogle Scholar
  124. 124.
    Federlin K, Pozza G. Indications for clinical islet transplantation today and in the foreseeable future-the diabetologist's point of view. J Mol Med. 1999;77:148–52.PubMedCrossRefGoogle Scholar
  125. 125.
    Choudhary RMR, Vantyghem M, Maffi P, Kay TW, Keymeulen B, Inagaki N, Saudek F, Lehmann R, Hering BJ. Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia. Diabetes Care. 2015;38:1016–29.PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Robertson RP. Islet transplantation for type 1 diabetes, 2015: what have we learned from alloislet and autoislet successes? Diabetes Care. 2015;38:1030–5.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Bosi E, Piatti P, Secchi A, Monti L, Traeger J, Dubernard J, Pozza G. Response of glucagon and insulin secretion to insulin-induced hypoglycemia in diabetic patients after pancreatic transplantation. Diab Nutr Metab. 1988;1:21–7.Google Scholar
  128. 128.
    Diem P, Redman J, Abid M, Moran A, Sutherland D, Halter J, Robertson R. Glucagon, catecholamine, and pancreatic polypeptide secretion in type I diabetic recipients of pancreas allografts. J Clin Invest. 1990;86:2008–13.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Bolinder J, Wahrenberg H, Persson A, Linde B, Tyden G, Groth C, Ostman J. Effect of pancreas transplantation on glucose counterregulation in insulin-dependent diabetic patients prone to severe hypoglycaemia. J Intern Med. 1991;230:527–33.PubMedCrossRefGoogle Scholar
  130. 130.
    Bolinder J, Wahrenberg H, Linde B, Tyden G, Groth C, Ostman J. Improved glucose counterregulation after pancreas transplantation in diabetic patients with unawareness of hypoglycemia. Transplant Proc. 1991;23:1667–9.PubMedGoogle Scholar
  131. 131.
    Landgraf R, Nusser J, Riepl R, Fiedler F, Illner W, Abendroth D, Land W. Metabolic and hormonal studies of type 1 (insulin-dependent) diabetic patients after successful pancreas and kidney transplantation. Diabetologia. 1991;34 Suppl 1:S61–7.PubMedCrossRefGoogle Scholar
  132. 132.
    Barrou Z, Seaquist E, Robertson R. Pancreas transplantation in diabetic humans normalizes hepatic glucose production during hypoglycemia. Diabetes. 1994;43:661–6.PubMedCrossRefGoogle Scholar
  133. 133.
    Kendall D, Rooney D, Smets Y, Bolding L, Robertson R. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing type 1 diabetes and autonomic neuropathy. Diabetes. 1997;46:249–57.PubMedCrossRefGoogle Scholar
  134. 134.
    Luzi L, Battezzati A, Perseghin G, Bianchi E, Vergani S, Secchi A, La Rocca E, Staudacher C, Spotti D, Ferrari G, Di Carlo V, Pozza G. Lack of feedback inhibition of insulin secretion in denervated human pancreas. Diabetes. 1992;41:1632–9.PubMedCrossRefGoogle Scholar
  135. 135.
    Battezzati A, Luzi L, Perseghin G, Bianchi E, Spotti D, Secchi A, Vergani S, Di Carlo V, Pozza G. Persistence of counter-regulatory abnormalities in insulin-dependent diabetes mellitus after pancreas transplantation. Eur J Clin Invest. 1994;24:751–8.PubMedCrossRefGoogle Scholar
  136. 136.
    Leitão CB, Tharavanij T, Cure P, Pileggi A, Baidal DA, Ricordi C, Alejandro R. Restoration of hypoglycemia awareness after islet transplantation. Diabetes Care. 2008;31(11):2113–5.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Paty BW, Ryan EA, Shapiro AM, Lakey JR, Robertson RP. Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence. Diabetes. 2002;51:3428–34.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Southlake Regional Health CenterNewmarketCanada
  2. 2.Department of MedicineUniversity of TorontoTorontoCanada
  3. 3.Department of MedicineUniversity of Rochester School of MedicineRochesterUSA

Personalised recommendations